Alcohol use in patients with hepatitis C virus (HCV) may result in a quicker progression to cirrhosis and liver cancer. Mavyret (glecaprevir-pibrentasvir) is used to treat patients with advancing HCV. Because there is a link between a more rapid progression of liver disease and the use of alcohol, clinicians typically suggest that all patients with HCV avoid alcohol use.

Chronic hepatitis C virus (HCV) and alcoholism commonly lead to liver disease in the US and around the world.

A specific alcohol (ethanol) drug interaction does not exist in the product labeling for Mavyret.

Studies of antivirals for HCV treatment usually required that patients have no or limited alcohol use, so the clinical outcomes of combining alcohol with these regimens are not well-defined. The exact amount of alcohol that might aggravate liver disease in HCV patients is not known.